Pancreatic cancer (PaC) is one of the most aggressive and highly lethal solid malignancies, with a 5-year survival of only 5%. Treatment of PaC is largely dependent on tumor size and location. Surgical resection, and/or chemoradiotherapy/chemotherapy are the most commonly used type of treatments in this solid malignancy.
Using primary research conducted with U.S., and European PaC medical oncologists, who have expertise treating PaC, this report provides a comprehensive analysis of the competitive landscape and market opportunity for PaC. This includes an analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies. Of the current therapies used to treat PaC, erlotinib (Roche/Astellas’s Tarceva), is currently the only targeted agent to gain regulatory approval in combination with chemotherapy in this indication. Nab-paclitaxel (Celgene’s Abraxane), a chemotherapy agent used in combination with gemcitabine is the latest and most commonly used addition to the PaC treatment armamentarium.
Questions Answered in This Report:
- The risk of PaC increases with age, with the highest incidence in people aged 65 or older. What is the size of the U.S. and EU5 (France, Germany, Italy, Spain, and the United Kingdom) PaC patient population, and how will it change over the next ten years? What are the key PaC drug treatable patient populations?
- The management and treatment of PaC patients can be highly complex given that tumor size and location dictate the involvement of certain medical experts and treatment options. What type of practitioner assumes care of PaC patients and does that differ depending on the stage of the disease and/or the geographical market? How are physicians currently managing treatment of PaC patients?
- Erlotinib (Roche/Astellas’s Tarceva), is currently the only targeted therapy approved for treatment of PaC, while nab-paclitaxel (Celgene’s Abraxane) is the last branded chemotherapy agent approved in this indication. How are erlotinib and nab-paclitaxel incorporated into the current treatment algorithm of PaC and does this differ between the markets under study? Do we forecast that this will change during our ten year forecast period (2014-2024)? What therapies in clinical development, if any, pose a threat to erlotinib and nab-paclitaxel’s current positioning?
- We have identified several unmet needs, challenges, and opportunities in the PaC landscape. What are the key unmet needs in the treatment of PaC according to interviewed thought leaders? Is it likely that these unmet needs will be addressed or partially addressed during our forecast period?
- There are several different drug classes in later-stage clinical development for PaC, such as modified cytotoxic agents, immunotherapies, or PARP and JAK inhibitors. What do experts interviewed think about the prospects of these emerging therapies? Which agents, if any, do we forecast will launch for treatment of PaC and how, if at all will this impact the PaC landscape?
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: 8 country-specific interviews with thought-leaders (medical oncologists).
Epidemiology: Diagnosed incident cases of PaC by stage of disease. Clinical- and market-relevant drug-treatable populations.
Emerging Therapies: Phase I: 3, Phase II: 6, Phase III: 6.
Michael Hughes, Ph.D.